drugset / Trial / NCT01687582
Effect of GLP-1 Analogs on Psoriasis in Type 2 Diabetic Patients
NaSingle-groupOpen-labelTreatment
Summary
The aim of the study is to evaluate after 4 to 6 months the effects of a GLP-1 analog treatment on psoriatic skin lesions in patients with type 2 diabetes.
Timeline
- Start
- 2012-01
- Primary completion
- 2012-12
- Completion
- 2013-03
Publications
- Background Buysschaert M, Tennstedt D, Preumont V. Improvement of psoriasis during exenatide treatment in a patient with diabetes. Diabetes Metab. 2012 Feb;38(1):86-8. doi: 10.1016/j.diabet.2011.11.004. Epub 2012 Jan 9.
- Background Hogan AE, Tobin AM, Ahern T, Corrigan MA, Gaoatswe G, Jackson R, O'Reilly V, Lynch L, Doherty DG, Moynagh PN, Kirby B, O'Connell J, O'Shea D. Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. Diabetologia. 2011 Nov;54(11):2745-54. doi: 10.1007/s00125-011-2232-3. Epub 2011 Jul 9.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Exenatide | Peptide | 5 ug | — |
| Subject | Exenatide | Peptide | 10 ug | — |
| Subject | Liraglutide | Peptide | 0.6 mg | — |
| Subject | Liraglutide | Peptide | 1.8 mg | — |